Idioma:

Treatment with enoxaparin adapted to the fertility programs in women with recurrent abortion and thrombophilia

Sarto, A ; Rocha, M ; Geller, M ; Capmany, C ; Martínez, M ; Quintans, C ; Donaldson, M ; Pasqualini, R S

Medicina (Buenos Aires), 2001, Vol.61 (4), p.406-412 [Periódico revisado por pares]

Argentina

Texto completo disponível

Citações Citado por

Enviar para

Título:
Treatment with enoxaparin adapted to the fertility programs in women with recurrent abortion and thrombophilia
Autor: Sarto, A ; Rocha, M ; Geller, M ; Capmany, C ; Martínez, M ; Quintans, C ; Donaldson, M ; Pasqualini, R S
Assuntos: Abortion, Habitual - etiology ; Abortion, Habitual - prevention & control ; Adult ; Biomarkers ; Embryo Loss - etiology ; Embryo Loss - prevention & control ; Enoxaparin - therapeutic use ; Female ; Fibrinolytic Agents - therapeutic use ; Heparin, Low-Molecular-Weight - therapeutic use ; Humans ; Infertility, Female - drug therapy ; Pregnancy ; Thrombophilia - complications ; Thrombophilia - diagnosis ; Thrombophilia - drug therapy
É parte de: Medicina (Buenos Aires), 2001, Vol.61 (4), p.406-412
Notas: ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
Descrição: Acquired and inherited thrombophilia are associated with recurrent pregnancy loss (RPL). Antithrombotic therapy could restore hemostatic balance and improve early placentation and gestational outcome. We evaluated the efficacy of enoxaparin adapted to the fertility program for prevention of pregnancy loss in 35 women (W) with early RPL and thrombophilia. Previous to the diagnosis of thrombophilia, they had had a total of 105 gestations of which 89 (85%) ended in early pregnancy loss. After diagnosis of thrombophilia, 35 subsequent pregnancies were treated with enoxaparin. In 5 cases assisted reproductive techniques were necessary to achieve pregnancy due to couple infertility. In 17 W who had had at least one preclinical pregnancy loss, enoxaparin (20 mg/d/s.c.) was started previous to conception and adapted to the fertility program. All the women continued with the gestational regime. Eighteen W with only clinical pregnancy loss started enoxaparin (20 mg twice per day s.c.) after biochemical pregnancy diagnosis. During gestations heparin dose was adjusted with anti Xa test, maintaining a range between 0.3 at 0.6 u/ml. With antithrombotic therapy, 30/35 (85%) of the pregnancies ended in live birth versus 16/105 (15%) of the pregnancies without treatment (p < 0.001). These results suggest that enoxaparin adapted to the fertility program can be effective in the prevention of preclinical and clinical abortion in women with thrombophilia.
Editor: Argentina
Idioma: Espanhol

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Treatment with enoxaparin adapted to the fertility programs in women with recurrent abortion and thrombophilia

Sarto, A ; Rocha, M ; Geller, M ; Capmany, C ; Martínez, M ; Quintans, C ; Donaldson, M ; Pasqualini, R S

Argentina

Buscando em bases de dados remotas. Favor aguardar.